ReviewFrontiers in immunology2026

Adjuvant therapy for renal cell carcinoma: lessons from past failures and new opportunities in the era of immune checkpoint inhibition.

Zengguang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.